• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA warns Valeant on SPAG-2 nebulizer, OraPharma OnSet mixing pen

November 9, 2016 By Sarah Faulkner

FDA warns Valeant on SPAG-2 nebulizer, OraPharma OnSet mixing penThe FDA this month warned Valeant Pharmaceuticals (NYSE:VRX) on violations found during inspections of its Rochester, N.Y., plant last summer.

The federal safety watchdog, in a Nov. 3 warning letter posted online today, wrote that inspections from Aug. 23 through Sept. 1 turned up problems with its small-particle aerosol generator, the SPAG-2 device, and a high-precision compound and dispensing pen, the OraPharma OnSet mixing pen.

The FDA flagged Laval, Canada-based Valeant for 5 violations of good manufacturing practices, corrective & preventive action, and maintaining adequate organizational structure, according to the letter:

  1. Failure to establish and maintain procedures for validating the device design;
  2. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verifications, review and approval of design changes before their implementation;
  3. Failure to establish and maintain procedures for implementing corrective and preventive action;
  4. Failure to establish and maintain procedures for to control product that does not conform to specified requirements;
  5. Failure to establish and maintain an adequate organizational structure to ensure that devices are designed and produced in accordance with the requirements of this part.

The violations come 1 week after news broke that Valeant is reportedly exploring a sale of its eye surgery business that could be worth as much as $2.5 billion. Valeant is in discussions with 3rd parties for “various divestitures”, according to the Wall Street Journal, although the company won’t give up the contact lenses, solutions and eye drugs that it acquired with its $9 billion purchase of Bausch & Lomb in 2013.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Respiratory Tagged With: Valeant Pharmaceuticals

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS